Cargando…
Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab
Treatment-pattern data suggest that some patients with multiple sclerosis (MS) in the Kingdom of Saudi Arabia (KSA) may not be receiving optimal treatment. A virtual meeting of ten expert Saudi neurologists, held on October 23, 2020, discussed unmet needs in relapsing–remitting MS (RRMS), and the ro...
Autores principales: | Craner, Matthew, Al Malik, Yaser, Babtain, Fawzi A., Alshamrani, Foziah, Alkhawajah, Mona M., Alfugham, Nora, Al-Yafeai, Rumaiza H., Aljarallah, Salman, Makkawi, Seraj, Qureshi, Shireen, Ziehn, Marina, Wahba, Hazem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434517/ https://www.ncbi.nlm.nih.gov/pubmed/36048334 http://dx.doi.org/10.1007/s40120-022-00401-4 |
Ejemplares similares
-
Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia
por: Alshamrani, Foziah, et al.
Publicado: (2021) -
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia
por: Al Jumah, Mohammed, et al.
Publicado: (2021) -
Spinal cord compression secondary to idiopathic thoracic epidural lipomatosis in an adolescent: A case report and review of literature
por: Al-Yafeai, Rumaiza, et al.
Publicado: (2017) -
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018) -
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
por: Baharnoori, Moogeh, et al.
Publicado: (2022)